X is hydrogen, halogen, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

Y is hydrogen, optionally substituted alkyl, or optionally substituted cycloalkyl; and

Z is an optionally substituted group chosen from N-heterocyclyl, -O-heterocyclylalkyl, -N(H)-heterocyclylalkyl, or -N(Me)-heterocyclylalkyl.

[0007] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. One embodiment provides a pharmaceutical composition comprising a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. One embodiment provides a pharmaceutical composition comprising a compound of Formula (Ib), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0008] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (I). One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (Ia). One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (Ib).

[0009] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof. One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (Ib), or a pharmaceutically acceptable salt thereof.

[0009a] In one embodiment, there is provided the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a patient in need thereof.

INCORPORATION BY REFERENCE

[0010] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein.

24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Y is hydrogen.

25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Y is optionally substituted cycloalkyl.

26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Y is optionally substituted alkyl.

27. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted alkyl is an optionally substituted C_1-C_3 alkyl.

28. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted alkyl is an optionally substituted C_1 alkyl.

29. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted alkyl is a methyl group.

30. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

31. A method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (I).

32. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a patient in need thereof.